| Document and Entity Information | Mar. 31, 2022 |
| Cover [Abstract] | |
| Amendment Flag | true |
| Entity Central Index Key | 0001492674 |
| Document Type | 8-K/A |
| Document Period End Date | Mar. 31, 2022 |
| Entity Registrant Name | T2 BIOSYSTEMS, INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-36571 |
| Entity Tax Identification Number | 20-4827488 |
| Entity Address, Address Line One | 101 Hartwell Avenue |
| Entity Address, City or Town | Lexington |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02421 |
| City Area Code | (781) |
| Local Phone Number | 761-4646 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common stock, par value $0.001 per share |
| Trading Symbol | TTOO |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Amendment Description | This Amendment No. 1 to the Current Report on Form 8-K amends Item 1.01 of the Current Report on Form 8-K filed on April 1, 2022 (the “Original Form 8-K”) solely to correct a typographical error in the description of the amount of funding being provided to T2 Biosystems, Inc., a Delaware corporation (the “Company”) by the Biomedical Advanced Research and Development Authority (“BARDA”) under Option 2B of the existing multiple-year cost-share contract between BARDA and the Company (the “BARDA Contract”). The Original Form 8-K incorrectly stated the amount as $44 million. The correct amount is $4.4. million. No other changes have been made to the Original Form 8-K. |
